A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip

NACompletedINTERVENTIONAL
Enrollment

357

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Osteoarthritis, Hip
Interventions
DEVICE

Synvisc-One (hylan G-F 20)

6-mL IA injection

DEVICE

Placebo

6 mL injection of phosphate buffered saline

Trial Locations (48)

10530

Investigational Site Number 840029, Hartsdale

14226

Investigational Site Number 840024, Amherst

14609

Investigational Site Number 840014, Rochester

16635

Investigational Site Number 840013, Altoona

19107

Investigational Site Number 840055, Philadelphia

19611

Investigational Site Number 840018, Reading

22901

Investigational Site Number 840016, Charlottesville

27612

Investigational Site Number 840028, Raleigh

28401

Investigational Site Number 840045, Wilmington

28801

Investigational Site Number 840044, Asheville

29464

Investigational Site Number 840026, Mt. Pleasant

30060

Investigational Site Number 840039, Marietta

32504

Investigational Site Number 840041, Pensacola

33134

Investigational Site Number 840049, South Miami

33316

Investigational Site Number 840036, Fort Lauderdale

33458

Investigational Site Number 840017, Jupiter

34232

Investigational Site Number 840047, Sarasota

34652

Investigational Site Number 840038, New Port Richey

35216

Investigational Site Number 840025, Burmingham

38163

Investigational Site Number 840052, Memphis

40509

Investigational Site Number 840012, Lexington

43213

Investigational Site Number 840046, Columbus

49648

Investigational Site Number 840033, Traverse City

60611

Investigational Site Number 840002, Chicago

63128

Investigational Site Number 840037, St Louis

67203

Investigational Site Number 840043, Wichita

75235

Investigational Site Number 840010, Dallas

76021

Investigational Site Number 840040, Bedford

78751

Investigational Site Number 840054, Austin

83642

Investigational Site Number 840005, Meridian

84020

Investigational Site Number 840011, Bradenton

Investigational Site Number 840009, Draper

84107

Investigational Site Number 840032, Salt Lake City

85016

Investigational Site Number 840042, Phoenix

85027

Investigational Site Number 840056, Phoenix

85712

Investigational Site Number 840004, Tucson

89502

Investigational Site Number 840007, Reno

90904

Investigational Site Number 840022, Santa Monica

91723

Investigational Site Number 840023, Covina

91942

Investigational Site Number 840058, La Mesa

98166

Investigational Site Number 840003, Seattle

06033

Investigational Site Number 840050, Farmington

06905

Investigational Site Number 840027, Stamford

06708

Investigational Site Number 840051, Waterbury

08234

Investigational Site Number 840048, Egg Harbor

N6C 4R3

Investigational Site Number 124091, London

H4N 3C5

Investigational Site Number 124093, Montreal

J1H 1Z1

Investigational Site Number 124092, Sherbrooke

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT01618708 - A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip | Biotech Hunter | Biotech Hunter